Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

Bibliography

• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;20:251-62
   Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 2010;463:88-94
   PubMed Web of Science ®Google Scholar
• Pleyer L, Egle A, Hartmann TN, Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405-18
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
   PubMed Web of Science ®Google Scholar
• Decouvelaere AV, Morschhauser F, Boub D, Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology 2007;50:561-6
   PubMed Web of Science ®Google Scholar
• Abrams ST, Lakum T, Lin K, B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C betaII. Blood 2007;109:1193-201
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Ghias K, Davies KM, Enzastaurin (LY317615), a protein kinase C beta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-9
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Koivula S, Nyman H, Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod Pathol 2010;23:686-93
   PubMed Web of Science ®Google Scholar
• Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs 2008;17:939-44
   PubMed Web of Science ®Google Scholar
• Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590-5
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
   PubMed Web of Science ®Google Scholar
• Moreau AS, Jia X, Ngo HT, Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim SG, Kim HP, Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916-26
   PubMed Web of Science ®Google Scholar
• Civallero M, Cosenza M, Grisendi G, Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 2010;51:671-9
   PubMed Web of Science ®Google Scholar
• Dumstorf CA, Konicek BW, McNulty AM, Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 2010;9:3158-63
   PubMedGoogle Scholar
• Guo K, Liu Y, Zhou H, Involvement of protein kinase C beta-extracellular signal-regulating kinase1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 2008;99:486-96
   PubMed Web of Science ®Google Scholar
• Kuo WL, Liu J, Mauceri H, Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther 2010;9:2814-24
   PubMed Web of Science ®Google Scholar
• Welch PA, Sinha VP, Cleverly AL, Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol 2007;47:1138-51
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS, Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9
   PubMed Web of Science ®Google Scholar
• Mukohara T, Nagai S, Koshiji M, Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors. Cancer Sci 2010;101:2193-9
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Stamaratis G, Opeskin K, Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma 2009;50:1666-75
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00332202?term=prelude&rank=1
   Google Scholar
• Naylor TL, Tang H, Ratsch BA, Protein kinase C inhibitor Sotrastaurin selectively inhibits the growth of CD79-mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-53
   PubMed Web of Science ®Google Scholar
• Rossi RM, Balys M, Franklin D, Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents. Blood (ASH Annual Meeting Abstracts) 2008;112:1595
   Google Scholar
• Haioun C, Morschhauser F, Jourdan E, Preliminary results of a Phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Morschhauser F, Seymour JF, Kluin-Nelemans HC, A Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53
   PubMed Web of Science ®Google Scholar
• Weinkauf M, Hutter G, Zimmermann Y, Enzastaurin treatment affects multiple regulatory pathways at transcriptome and cellular proteome level of mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2010;116:2893
   Google Scholar
• Hutter G, Zimmermann Y, Weinkauf M, The Functional impact of PKCbeta/PI3K/AKT signaling on translational initiation in MCL. Blood (ASH Annual Meeting Abstracts) 2008;112:2624
   Google Scholar
• Schwartzberg L, Hermann RC, Flinn IW, Enzastaurin in patients with follicular lymphoma: Results of a Phase II study. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Irish JM, Myklebust JH, Alizadeh AA, B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 2010;107:12747-54
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009:532-41
   PubMedGoogle Scholar
• Kheirallah S, Ysebaert L, Leseux L, Enzastaurin displays activity against follicular lymphoma cells: role of mTOR pathway. Blood (ASH Annual Meeting Abstracts) 2008;112:2609
   Google Scholar
• Leseux L, Laurent G, Laurent C, PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008;111:285-91
   PubMed Web of Science ®Google Scholar
• Kheirallah S, Caron P, Gross E, Rituximab inhibits B-cell receptor signaling. Blood 2010;115:985-94
   PubMed Web of Science ®Google Scholar
• Ogbomo H, Biru T, Michaelis M, The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3beta. Biochem Pharmacol 2011;81:251-8
   PubMed Web of Science ®Google Scholar
• Forsyth CJ, Gomez D, Eliadis P, Enzastaurin in Patients with Non-Hodgkin Lymphomas: A Multicenter, Open-Label, Screening Study. Blood (ASH Annual Meeting Abstracts) 2009;114:3719
   Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47
   PubMed Web of Science ®Google Scholar
• Holler C, Pinon JD, Denk U, PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791-4
   PubMed Web of Science ®Google Scholar
• Zum Buschenfelde CM, Wagner M, Lutzny G, Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141-52
   PubMed Web of Science ®Google Scholar
• Raab MS, Breitkreutz I, Tonon G, Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009;113:1513-21
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Harousseau JL, Treon SP, Enzastaurin in previously treated Waldenstrom's macroglobulinemia: an open-label, multicenter, Phase II study. Blood (ASH Annual Meeting Abstracts) 2009;114:3867
   Web of Science ®Google Scholar
• Hanauske AR, Eismann U, Oberschmidt O, Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells. Invest New Drugs 2008;26:215-22
   PubMed Web of Science ®Google Scholar
• Evenou JP, Wagner J, Zenke G, The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009;330:792-801
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010;2010:265-70
   PubMedGoogle Scholar
• Podar K, Raab MS, Chauhan D, The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16:1693-707
   PubMed Web of Science ®Google Scholar